CAMBRIDGE, Mass., Oct. 27 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Ian Fier, Vice President, Development Operations, will present at the MBC Mass Opportunities Biotechnology Investment Conference on Thursday, November 2, 2006 at 11:10 am EST at the Hilton at Logan Airport, Boston, MA. A live audio webcast of the presentation will be available on the "Investors" section of the Company's website located at http://www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately thirty minutes after the event and will be available through December 2, 2006.
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed characterization and engineering of complex sugars and other complex mixtures. Momenta is applying its technology to create technology-enabled generic versions of sugar-based and other complex drug products, develop improved versions of existing drugs, and discover novel drugs and new biological processes. The Company's most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox®. Momenta's first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. The Company is developing other novel drug candidates through its discovery effort focused on understanding sugar-based biological processes. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit our website at http://www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Michael A. Lawless Momenta Pharmaceuticals, Inc. 617-395-5189
SOURCE Momenta Pharmaceuticals, Inc.